← FDA DRUG APPROVALS

FDA NDA · NDA021712

FLUXID

Sponsor: UCB INC

APPLICATION
NDA021712
TYPE
NDA
ORIGINAL APPROVAL
2004-09-24
LATEST ACTION
2004-09-24
ROUTE
ORAL
DOSAGE FORM
TABLET, ORALLY DISINTEGRATING
MARKETING STATUS
Discontinued

Products

FLUXIDDiscontinued
FAMOTIDINE 20MG · TABLET, ORALLY DISINTEGRATING · ORAL
FLUXIDDiscontinued
FAMOTIDINE 40MG · TABLET, ORALLY DISINTEGRATING · ORAL

Approval history

2004-09-24Type 3 - New Dosage Form · Original · standard — Letter ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →